Beijing has begun inoculating China's first multivalent vaccine that can provide broad spectrum protection against COVID variants, developed by Chinese vaccine producer Sinocelltech with clinical research data showing that it has the advantages in safety and immunity persistence.
At the beginning of December 2022, Sinocelltech's COVID recombinant protein bivalent vaccine was approved for emergency use, and has since been recommended by the country's second booster for enhanced immunization plan, according to media reports.
Sinocelltech's clinical trials both at home and abroad have demonstrated that the vaccine is highly effective against existing omicron strains BA.1 and BA.5, and has the potential to work against future variants too, the firm was quoted as saying in previous media reports.
Some hospitals in Beijing have already received the vaccine, for example, in Yizhuang area, southeast suburb of the capital city, local residents can be inoculated with Sinocelltech's bivalent vaccine, in addition to the previous four types of COVID vaccines.